Glazener C M, Evans J H
Health Services Research Unit (Flea), University of Aberdeen, Foresterhill Lea, Foresterhill, Aberdeen, Aberdeenshire, UK, AB25 2ZD.
Cochrane Database Syst Rev. 2000(2):CD002117. doi: 10.1002/14651858.CD002117.
Enuresis (bedwetting) is a socially unacceptable and stressful condition which affects around 15-20% of five year olds, and up to 2% of young adults. Although there is a high rate of spontaneous remission, the social, emotional and psychological costs to the children can be great.
To assess the effects of tricyclic and related drugs on nocturnal enuresis in children, and to compare them with other interventions.
The following electronic databases were searched: MEDLINE to June 1997; AMED; ASSIA; BIDS; BIOSIS Previews (1985-1996); CINAHL; DHSS Data; EMBASE (1974 to June 1997); PsycLIT and SIGLE. Organisations, manufacturers, researchers and health professionals concerned with enuresis were contacted for information. The reference sections of obtained studies were also checked for further trials. Date of the most recent search: July 1997.
All randomised trials of tricyclic and related drugs for nocturnal enuresis in children were included in the review. Trials were eligible for inclusion if: children were randomised to receive tricyclics compared with placebo, other drugs or other conservative interventions for nocturnal bedwetting; participants with organic causes for their bedwetting were excluded; and baseline assessments of the level of bedwetting were provided. Trials focused solely on daytime wetting were excluded.
Two reviewers independently assessed the quality of the eligible trials, and extracted data.
Twenty two randomised trials, involving 1100 children treated with tricyclic or related drugs, met the inclusion criteria. The quality of many of the trials was poor. Only single trials compared tricyclic or related drugs with each other, other drugs, desmopressin, alarms or other behavioural interventions. Treatment with tricyclic drugs (such as imipramine, amitriptyline, viloxazine, clomipramine and desipramine but not mianserin) were associated with a reduction of about one wet night per week while on treatment (eg using imipramine, WMD -0.99, 95% CI -1.27 to -0.71). Children were almost five times more likely to achieve 14 dry nights with the drugs (eg using imipramine, RR = 4.99, 95% CI 2.4 to 10.40). Desmopressin and tricyclics appeared equally effective while on treatment, but this effect was not sustained after treatment stopped. There was no detectable difference between imipramine and alarms while on treatment, but afterwards those who had used alarms had one fewer wet night per week (WMD 1.03, 95% CI 0. 19 to 1.87).
REVIEWER'S CONCLUSIONS: Treatment with tricyclic drugs (imipramine, amitriptyline, viloxazine, clomipramine and desipramine but not mianserin) was associated with a reduction of about one wet night per week while on treatment, but long term effectiveness is unknown. Desmopressin and tricyclics appeared equally effective while on treatment, but this effect was not sustained after treatment stopped. Alarms may be more effective in the long term. Comparisons between drug and behavioural treatments are needed, and should include relapse rates after treatment is finished.
遗尿症(尿床)是一种不被社会所接受且会带来压力的状况,约15% - 20%的五岁儿童以及高达2%的年轻人受其影响。尽管自然缓解率较高,但对儿童造成的社会、情感和心理代价可能很大。
评估三环类及相关药物对儿童夜间遗尿症的疗效,并与其他干预措施进行比较。
检索了以下电子数据库:截至1997年6月的MEDLINE;AMED;ASSIA;BIDS;BIOSIS Previews(1985 - 1996年);CINAHL;卫生与社会保障部数据;EMBASE(1974年至1997年6月);PsycLIT和SIGLE。还联系了与遗尿症相关的组织、制造商、研究人员和卫生专业人员以获取信息。对所获研究的参考文献部分也进行了检查以寻找更多试验。最近一次检索日期:1997年7月。
纳入所有关于三环类及相关药物治疗儿童夜间遗尿症的随机试验。若试验符合以下条件则 eligible for inclusion:儿童被随机分组,接受三环类药物治疗,并与安慰剂、其他药物或其他治疗夜间尿床的保守干预措施进行比较;排除有尿床器质性病因的参与者;提供尿床水平的基线评估。仅关注日间遗尿的试验被排除。
两名评价者独立评估符合条件的试验质量并提取数据。
22项随机试验符合纳入标准,涉及1100名接受三环类或相关药物治疗的儿童。许多试验质量较差。仅有单个试验将三环类或相关药物相互之间、与其他药物、去氨加压素、报警器或其他行为干预措施进行了比较。使用三环类药物(如丙咪嗪、阿米替林、维洛沙嗪、氯米帕明和地昔帕明,但不包括米安色林)治疗时,每周尿床次数减少约一次(如使用丙咪嗪,加权均数差 -0.99,95%置信区间 -1.27至 -0.71)。使用这些药物使儿童连续14个干爽夜晚的可能性几乎高出四倍(如使用丙咪嗪,相对危险度 = 4.99,95%置信区间2.4至10.40)。治疗期间,去氨加压素和三环类药物似乎同样有效,但停药后这种效果未持续。治疗期间,丙咪嗪和报警器之间未发现可检测到的差异,但之后使用报警器的儿童每周尿床次数少一次(加权均数差1.03,95%置信区间0.19至1.87)。
使用三环类药物(丙咪嗪、阿米替林、维洛沙嗪、氯米帕明和地昔帕明,但不包括米安色林)治疗时,每周尿床次数减少约一次,但长期疗效未知。治疗期间,去氨加压素和三环类药物似乎同样有效,但停药后这种效果未持续。从长远来看,报警器可能更有效。需要对药物治疗和行为治疗进行比较,且应包括治疗结束后的复发率。